Jeremie Calais, MD
"68GA-PSMA-11 PET/CT detects prostate cancer at early biochemical recurrence with superior detection rate and reader agreement when compared to 18F-Fluciclovine PET/CT in a prospective head to head comparative phase 3 study"
Sungwook Jung, PhD
“Natural Killer cell labeled by gold-coated iron oxide nanoparticles: PET/MRI/PA monitoring and immuno-photothermal cancer therapy"
Raiyan Tripti Zaman, PhD
“Harnessing Radioluminescence and Sound to Reveal Molecular Pathology of Atherosclerotic Plaques"
“Prognostic Value of Pre-treatment Ga-68-RGD PET-CT in Predicting Disease Free Survival in Patients with Breast Cancer: A Comparison Study with Dynamic Contrast Enhanced MRI.”
"SPECT/CT to quantify eosinophil migration into the lungs"
Personalized 177 Lu-octreotate PPRT: cycle-to-cycle renal radiation dose prediction using quantitative SPECT/CT dosimetry
Matthias Eiber, MD, PhD
“Initial experience in restaging of patients with recurrent prostate cancer: Comparison of 11C-Choline-PET/MR and 11C-Choline-PET/CT”
Hai Jeon Yoon, MD
"Predicting histologic biomarker expression in breast cancer with 68Ga-RGD PET/CT versus diffusion-weighted and dynamic contrast-enhanced MRI"
Masahiro Yanagawa, MD, PhD
"Comparison of PET Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) in neoadjuvant chemotherapy for esophageal cancer"
Andrew Quon, MD
“Correlation between MRI and NaF PET/CT in patients with patellofemoral knee pain”
Patrick Veit-Haibach, MD
“Impact of F18-DOPA PET/CT on therapeutic management in patients neuroendocrine tumors”
Donna J. Cross, PhD
“Olfactory tract dysintegrity and cortical metabolic change in aging and MCI.”
Jan Soyka, MD
"Staging Pathways in Recurrent Colorectal Carcinoma. Is Contrast-enhanced 18-FDG-PET-CT the Diagnostic Tool of Choice?"